Quantification of the FLT3 internal tandem duplication is a reliable marker for monitoring measurable residual disease in acute myeloid leukemia with FLT3-ITD mutations

doi:10.1038/s41409-024-02495-w

. 2025 Mar;60(3):412-414.

doi: 10.1038/s41409-024-02495-w. Epub 2024 Dec 10.

Quantification of the FLT3 internal tandem duplication is a reliable marker for monitoring measurable residual disease in acute myeloid leukemia with FLT3-ITD mutations

Meng-Miao Wang^#^{1

2

3}, Si-Man Huang^#^{2

3}, Yuan-Hong Huang^#^{2

3}, Jian Zhang^#⁴, Hui-Ying Li^{2

3}, Shuai-Shuai Ge^{2

3}, Chao-Ling Wan^{2

3}, Miao Wang^{2

3}, Hai-Hui Liu^{2

3}, Han-Yu Cao^{2

3}, Zi-Hao Wang^{2

3}, Kai-Wen Tan^{2

3}, Hong-Feng Pang^{2

3}, Xiao-Yu Lyu^{2

3}, Song-Bai Liu⁵, Hai-Ping Dai^{6

7}, Sheng-Li Xue^{8

9}, Qiao-Cheng Qiu^{10

11}

Affiliations

¹ Department of Hematology, Qinghai Provincial People's Hospital, Xining, China.
² National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
³ Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Suzhou University, Suzhou, China.
⁴ Department of Blood Transfusion, The First Affiliated Hospital of Soochow University, Suzhou, China.
⁵ Suzhou Key Laboratory of Medical Biotechnology, Suzhou Vocational Health College, Suzhou, China. liusongbai@126.com.
⁶ National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China. daihaiping8@126.com.
⁷ Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Suzhou University, Suzhou, China. daihaiping8@126.com.
⁸ National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China. slxue@suda.edu.cn.
⁹ Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Suzhou University, Suzhou, China. slxue@suda.edu.cn.
¹⁰ National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China. qiuqiaocheng@163.com.
¹¹ Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Suzhou University, Suzhou, China. qiuqiaocheng@163.com.

^# Contributed equally.

PMID: 39658655
DOI: 10.1038/s41409-024-02495-w

Quantification of the FLT3 internal tandem duplication is a reliable marker for monitoring measurable residual disease in acute myeloid leukemia with FLT3-ITD mutations

Meng-Miao Wang et al. Bone Marrow Transplant. 2025 Mar.

. 2025 Mar;60(3):412-414.

doi: 10.1038/s41409-024-02495-w. Epub 2024 Dec 10.

Authors

Affiliations

¹ Department of Hematology, Qinghai Provincial People's Hospital, Xining, China.
² National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
³ Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Suzhou University, Suzhou, China.
⁴ Department of Blood Transfusion, The First Affiliated Hospital of Soochow University, Suzhou, China.
⁵ Suzhou Key Laboratory of Medical Biotechnology, Suzhou Vocational Health College, Suzhou, China. liusongbai@126.com.
⁶ National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China. daihaiping8@126.com.
⁷ Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Suzhou University, Suzhou, China. daihaiping8@126.com.
⁸ National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China. slxue@suda.edu.cn.
⁹ Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Suzhou University, Suzhou, China. slxue@suda.edu.cn.
¹⁰ National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China. qiuqiaocheng@163.com.
¹¹ Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Suzhou University, Suzhou, China. qiuqiaocheng@163.com.

^# Contributed equally.

PMID: 39658655
DOI: 10.1038/s41409-024-02495-w

No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests: The authors declare no competing interests. Ethics approval and consent to participate: This study was approved by the Ethics Committee of the First Affiliated Hospital of Soochow University (2022-316). Patient data were collected after informed consent was obtained in accordance with the Declaration of Helsinki.

Cited by

Significance of Measurable Residual Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia.
Gang M, Othus M, Walter RB. Gang M, et al. Cells. 2025 Feb 15;14(4):290. doi: 10.3390/cells14040290. Cells. 2025. PMID: 39996762 Free PMC article. Review.

References

1. Gale RE, Green C, Allen C, Mead AJ, Burnett AK, Hills RK, et al. Medical Research Council Adult Leukaemia Working Party. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood. 2008;111:2776–84. - DOI - PubMed
1. Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345–77. - DOI - PubMed
1. Zhao JC, Agarwal S, Ahmad H, Amin K, Bewersdorf JP, Zeidan AM. A review of FLT3 inhibitors in acute myeloid leukemia. Blood Rev. 2022;52:100905. - DOI - PubMed
1. Grob T, Sanders MA, Vonk CM, Kavelaars FG, Rijken M, Hanekamp DW, et al. Prognostic value of FLT3-Internal tandem duplication residual disease in acute myeloid leukemia. J Clin Oncol. 2023;41:756–65. - DOI - PubMed
1. Liu SB, Qiu QC, Bao XB, Ma X, Li HZ, Liu YJ, et al. Pattern and prognostic value of FLT3-ITD mutations in Chinese de novo adult acute myeloid leukemia. Cancer Sci. 2018;109:3981–92. - DOI - PubMed - PMC

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
Miscellaneous
- NCI CPTAC Assay Portal

[1] Gale RE, Green C, Allen C, Mead AJ, Burnett AK, Hills RK, et al. Medical Research Council Adult Leukaemia Working Party. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood. 2008;111:2776–84. - DOI - PubMed

[2] Gale RE, Green C, Allen C, Mead AJ, Burnett AK, Hills RK, et al. Medical Research Council Adult Leukaemia Working Party. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood. 2008;111:2776–84. - DOI - PubMed

[3] Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345–77. - DOI - PubMed

[4] Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345–77. - DOI - PubMed

[5] Zhao JC, Agarwal S, Ahmad H, Amin K, Bewersdorf JP, Zeidan AM. A review of FLT3 inhibitors in acute myeloid leukemia. Blood Rev. 2022;52:100905. - DOI - PubMed

[6] Zhao JC, Agarwal S, Ahmad H, Amin K, Bewersdorf JP, Zeidan AM. A review of FLT3 inhibitors in acute myeloid leukemia. Blood Rev. 2022;52:100905. - DOI - PubMed

[7] Grob T, Sanders MA, Vonk CM, Kavelaars FG, Rijken M, Hanekamp DW, et al. Prognostic value of FLT3-Internal tandem duplication residual disease in acute myeloid leukemia. J Clin Oncol. 2023;41:756–65. - DOI - PubMed

[8] Grob T, Sanders MA, Vonk CM, Kavelaars FG, Rijken M, Hanekamp DW, et al. Prognostic value of FLT3-Internal tandem duplication residual disease in acute myeloid leukemia. J Clin Oncol. 2023;41:756–65. - DOI - PubMed

[9] Liu SB, Qiu QC, Bao XB, Ma X, Li HZ, Liu YJ, et al. Pattern and prognostic value of FLT3-ITD mutations in Chinese de novo adult acute myeloid leukemia. Cancer Sci. 2018;109:3981–92. - DOI - PubMed - PMC

[10] Liu SB, Qiu QC, Bao XB, Ma X, Li HZ, Liu YJ, et al. Pattern and prognostic value of FLT3-ITD mutations in Chinese de novo adult acute myeloid leukemia. Cancer Sci. 2018;109:3981–92. - DOI - PubMed - PMC

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Quantification of the FLT3 internal tandem duplication is a reliable marker for monitoring measurable residual disease in acute myeloid leukemia with FLT3-ITD mutations

Affiliations

Quantification of the FLT3 internal tandem duplication is a reliable marker for monitoring measurable residual disease in acute myeloid leukemia with FLT3-ITD mutations

Authors

Affiliations

Conflict of interest statement

Similar articles

Cited by

References

Publication types

LinkOut - more resources

Full Text Sources

Miscellaneous